Incyte Corp.INCY

Close of Friday, October 23, 2026 · Incyte Corp. is trading above its Pivot, OnlyAlpha's long-term trend line.

Price

$115.70

vs its Pivot

+7.3%

OnlyAlpha Score

Trend

Above its Pivot

Last 12 months. Solid line: price. Dashed green: the Pivot.

Returns

1 month	Year to date	1 year	3 years / yr	5 years / yr
-7.0%	+17.1%	+31.4%	+26.8%	+12.0%

No dividend in the last 12 months.

Who runs and owns it

In these funds

IBB · 1.69%IYH · 0.32%IVV · 0.03%IYY · 0.03%

Big investors that own it (latest 13F)

Baker Bros. Advisors	17.5% of holdings
Renaissance Technologies	0.6% of holdings

Suppliers, customers and partners

Sells to INCY

MacroGenics	retifanlimab
Xencor	tafasitamab
Syndax Pharmaceuticals	axatilimab

INCY sells to

Eli Lilly	Olumiant (baricitinib) royalties
Novartis	Jakavi ex-US royalties

From the companies' own annual reports filed with the SEC.

Healthcare · Biotech

ACET -49%ALNY -23%ARGX +2%ARWR -19%ASND +3%AXSM -28%BBIO -6%BCAX -20%BIIB +26%BMRN -4%BNTX -10%CORT +17%

Get INCY in your free daily emailAfter every close: whether INCY is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track INCY free → Full Stock check